The cancer-testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo

Molecular Medicine Reports

Volumn 8, Issue 5, 2013, Pages 1549-1555

  Zhou, Jihao ^a   Li, Yonghui ^a   Yao, Yushi ^a   Wang, Lixin ^a   Gao, Li ^a   Gao, Xiaoning ^a   Luo, Xufeng ^a   Li, Jingxin ^a   Jiang, Mengmeng ^a   Zhou, Minhang ^a   Wang, Lili ^a   Yu, Li ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Acute leukemia; Cancer testis antigens; Decitabine; Methylation; Nuclear RNA export factor 2

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIGEN; NUCLEAR RNA EXPORT FACTOR 2 ANTIGE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DRUG TARGETING; EPIGENETIC REPRESSION; EPIGENETICS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PROTEIN EXPRESSION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CPG ISLANDS; DNA METHYLATION; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NUCLEOCYTOPLASMIC TRANSPORT PROTEINS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA-BINDING PROTEINS; TUMOR CELLS, CULTURED;

EID: 84885132513     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1659     Document Type: Article

References (25)

1. Fratta E, Coral S, Covre A, et al: The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol 5: 164-182, 2011.
2. van der Bruggen P, Traversari C, Chomez P, et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991.
3. Weber J, Salgaller M, Samid D, et al: Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res 54: 1766-1771, 1994.
4. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F and Boon T: The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA 93: 7149-7153, 1996.
5. van Baren N, Chambost H, Ferrant A, et al: PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 102: 1376-1379, 1998.
6. Chen YT, Boyer AD, Viars CS, Tsang S, Old LJ and Arden KC: Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28. Cytogenet Cell Genet 79: 237-240, 1997.
7. Gure AO, Türeci O, Sahin U, et al: SSX: a multigene family with several members transcribed in normal testis and human cancer. Int J Cancer 72: 965-971, 1997.
8. Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, et al: The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res 34: 899-905, 2010.
9. + T cells against NY-ESO-1. N Engl J Med 358: 2698-2703, 2008.
10. Fradet Y, Picard V, Bergeron A and LaRue H: Cancer-testis antigen expression in bladder cancer. Prog Urol 15 (Suppl 1): 1303-1313, 2005.
11. Calabrò L, Fonsatti E, Altomonte M, et al: Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications. J Cell Physiol 202: 474-477, 2005.
12. Wang PJ, McCarrey JR, Yang F and Page DC: An abundance of X-linked genes expressed in spermatogonia. Nat Genet 27: 422-426, 2001.
13. Takano K, Miki T, Katahira J and Yoneda Y: NXF2 is involved in cytoplasmic mRNA dynamics through interactions with motor proteins. Nucleic Acids Res 35: 2513-2521, 2007.
14. Chen CP, Su YN, Lin HH, et al: De novo duplication of Xq22.1→q24 with a disruption of the NXF gene cluster in a mentally retarded woman with short stature and premature ovarian failure. Taiwan J Obstet Gynecol 50: 339-344, 2011.
15. Pan J, Eckardt S, Leu NA, et al: Inactivation of Nxf2 causes defects in male meiosis and age-dependent depletion of spermatogonia. Dev Biol 330: 167-174, 2009.
16. Stouffs K, Tournaye H, Van der Elst J, Liebaers I and Lissens W: Is there a role for the nuclear export factor 2 gene in male infertility? Fertil Steril 90: 1787-1791, 2008.
17. Chen YT, Ross DS, Chiu R, et al: Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One 6: e17876, 2011.
18. Dubovsky JA, McNeel DG, Powers JJ, Gordon J, Sotomayor EM and Pinilla-Ibarz JA: Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res 15: 3406-3415, 2009.
19. Jaatinen T and Laine J: Isolation of mononuclear cells from human cord blood by Ficoll-Paque density gradient. Curr Protoc Stem Cell Biol Chapter 2: Unit 2A.1, 2007.
20. Lübbert M, Ruter BH, Claus R, et al: A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 97: 393-401, 2012.
21. van Dongen JJ, Macintyre EA, Gabert JA, et al: Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13: 1901-1928, 1999.
22. Li CS, Chen C, Zheng P and Liu Y: Transgenic expression of P1A induced thymic tumor: a role for onco-fetal antigens in tumorigenesis. PLoS One 5: e13439, 2010.
23. Li LC and Dahiya R: MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427-1431, 2002.
24. Quintarelli C, Dotti G, Hasan ST, et al: High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood 117: 3353-3362, 2011.
25. Yan M, Himoudi N, Basu BP, et al: Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-aza-2′-deoxycytidine. Cancer Immunol Immunother 60: 1243-1255, 2011.